Daniel Chen is in an ideal position to weigh in on the past, present and future of cancer immunotherapy.
From 2006 to 2018 he worked for Genentech and Roche serving as the global head of the cancer immunotherapy franchise for the last four years. (Also see "INTERVIEW: Roche's Dan Chen Talks Immuno-Oncology Combinations" - Scrip, 24 June, 2016
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?